Year-end Sale % OFF 
Abstract
SummaryIn a multi-centre assessment of 887 hypertensive patients, treatment with the nonselective ^-receptor antagonist oxprenolol was substituted, in part or completely, for the adrenergic neurone blockers, bethanidine, debrisoquine or guanethidine. The results showed that after the gradual introduction, over approximately 10 weeks, of oxprenolol in a median daily dose of 200 mg. (range 80 mg. to 480 mg.) there was a significant reduction in blood pressure, particularly systolic levels. The incidence of troublesome side-effects associated with the three adrenergic neurone blockers, such as postural and exercise hypotension, tiredness, diarrhoea and impotence, was markedly reduced, with an accompanying improvement in the quality of the patient's life.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
